Crowley N J, Slingluff C L, Darrow T L, Seigler H F
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Cancer Res. 1990 Feb 1;50(3):492-8.
Autologous tumor-specific cytotoxic T-lymphocytes (CTLs), generated by repeated stimulation with autologous melanoma and expanded in interleukin 2, are major histocompatibility complex restricted. These CTLs recognize a common tumor-associated antigen in the presence of HLA class I determinants, suggesting that allogeneic melanomas which express the restricting HLA-A region antigen could substitute for the autologous tumor in the generation of CTLs. This was investigated in the HLA-A2 system. Four T-cell lines were established by stimulation of lymphocytes with either autologous tumor or an HLA-A2-matched allogeneic melanoma. Allogeneic stimulated CTLs specifically lysed the autologous tumor and demonstrated an identical pattern of HLA-A2 restriction, when compared to the autologous stimulated CTLs. Lysis by the allogeneic stimulated CTLs was blocked by a monoclonal antibody to HLA class I antigens; lysis was also inhibited by both autologous tumor or HLA-A2 allogeneic melanomas when evaluated in cold target competition studies. The allogeneic stimulated CTLs proliferated in response to both autologous tumor and HLA-A2 melanomas, but not in response to HLA-A2 nonmelanomas. By phenotypic analysis these CTLs were CD3+ and predominantly CD8+ cells. We conclude that autologous tumor-specific CTLs can be generated using HLA-A region-matched allogeneic melanomas for stimulation. Since established, HLA-typed melanoma tumor lines can be used in the absence of autologous tumor; this procedure can be applied clinically to a broad patient population and may prove useful in the adoptive immunotherapy of melanoma.
通过用自体黑色素瘤反复刺激并在白细胞介素 2 中扩增产生的自体肿瘤特异性细胞毒性 T 淋巴细胞(CTL)受主要组织相容性复合体限制。这些 CTL 在 HLA I 类决定簇存在的情况下识别一种常见的肿瘤相关抗原,这表明表达限制性 HLA - A 区域抗原的同种异体黑色素瘤可以替代自体肿瘤用于产生 CTL。在 HLA - A2 系统中对此进行了研究。通过用自体肿瘤或 HLA - A2 匹配的同种异体黑色素瘤刺激淋巴细胞建立了四个 T 细胞系。与自体刺激的 CTL 相比,同种异体刺激的 CTL 特异性裂解自体肿瘤并表现出相同的 HLA - A2 限制模式。同种异体刺激的 CTL 的裂解被针对 HLA I 类抗原的单克隆抗体阻断;在冷靶竞争研究中评估时,自体肿瘤或 HLA - A2 同种异体黑色素瘤也抑制裂解。同种异体刺激的 CTL 对自体肿瘤和 HLA - A2 黑色素瘤均有增殖反应,但对 HLA - A2 非黑色素瘤无反应。通过表型分析,这些 CTL 是 CD3 + 且主要是 CD8 + 细胞。我们得出结论,使用 HLA - A 区域匹配的同种异体黑色素瘤进行刺激可以产生自体肿瘤特异性 CTL。由于已建立,在没有自体肿瘤的情况下可以使用 HLA 分型的黑色素瘤肿瘤系;该程序可临床应用于广泛的患者群体,并且可能在黑色素瘤的过继免疫治疗中证明有用。